Spark Therapeutics Inc (NASDAQ:ONCE) – Equities researchers at SunTrust Banks dropped their FY2018 earnings estimates for shares of Spark Therapeutics in a note issued to investors on Tuesday, November 6th. SunTrust Banks analyst E. Nash now anticipates that the biotechnology company will post earnings of ($1.58) per share for the year, down from their prior estimate of ($0.94). SunTrust Banks currently has a “Buy” rating and a $61.00 price target on the stock. SunTrust Banks also issued estimates for Spark Therapeutics’ Q4 2018 earnings at ($1.21) EPS, Q1 2019 earnings at ($1.10) EPS, Q2 2019 earnings at ($1.13) EPS, Q3 2019 earnings at ($1.04) EPS, Q4 2019 earnings at ($1.01) EPS, FY2019 earnings at ($3.59) EPS, FY2020 earnings at ($3.44) EPS, FY2021 earnings at ($3.16) EPS and FY2022 earnings at ($1.21) EPS.

Spark Therapeutics (NASDAQ:ONCE) last released its earnings results on Tuesday, November 6th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.04) by ($0.22). Spark Therapeutics had a negative return on equity of 14.18% and a negative net margin of 127.82%. The business had revenue of $10.70 million for the quarter, compared to analyst estimates of $27.44 million. During the same quarter in the previous year, the firm posted ($1.90) EPS. The business’s revenue for the quarter was up 463.2% on a year-over-year basis.

Several other equities analysts have also recently issued reports on ONCE. Cantor Fitzgerald set a $103.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a research report on Monday, July 16th. Royal Bank of Canada cut Spark Therapeutics from an “outperform” rating to a “sector perform” rating and set a $100.00 target price on the stock. in a research report on Thursday, July 19th. ValuEngine cut Spark Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 24th. Citigroup upgraded Spark Therapeutics from a “neutral” rating to a “buy” rating in a research report on Tuesday, August 7th. Finally, Leerink Swann reiterated a “market perform” rating and set a $55.00 target price (down previously from $74.00) on shares of Spark Therapeutics in a research report on Tuesday, August 7th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $68.52.

NASDAQ ONCE opened at $42.76 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.14 and a current ratio of 10.71. Spark Therapeutics has a 12-month low of $39.01 and a 12-month high of $96.59. The company has a market cap of $1.71 billion, a price-to-earnings ratio of -5.60 and a beta of 2.27.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Trexquant Investment LP acquired a new stake in shares of Spark Therapeutics in the 3rd quarter worth approximately $881,000. Elk Creek Partners LLC grew its holdings in Spark Therapeutics by 107.6% during the 3rd quarter. Elk Creek Partners LLC now owns 215,728 shares of the biotechnology company’s stock valued at $11,768,000 after buying an additional 111,820 shares during the last quarter. BlackRock Inc. grew its holdings in Spark Therapeutics by 5.6% during the 3rd quarter. BlackRock Inc. now owns 3,031,043 shares of the biotechnology company’s stock valued at $165,344,000 after buying an additional 161,811 shares during the last quarter. Alliancebernstein L.P. grew its holdings in Spark Therapeutics by 38.3% during the 3rd quarter. Alliancebernstein L.P. now owns 531,184 shares of the biotechnology company’s stock valued at $28,976,000 after buying an additional 147,158 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky grew its holdings in Spark Therapeutics by 31.5% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 40,611 shares of the biotechnology company’s stock valued at $2,215,000 after buying an additional 9,717 shares during the last quarter.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

See Also: What is a Market Correction?

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.